Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Cuts Q4 Revenue Projection for Second Time

NEW YORK, Jan. 6 (GenomeWeb News) - Affymetrix announced yesterday cut its fourth-quarter revenue projections by roughly $15 million, or 12.5 percent, below previous guidance.


The company blamed the cut, which is the second one in three months, on low fourth-quarter instrument sales and delays in completing genotyping processing under a services contract.


Affymetrix had originally projected its Q4 revenues to be $130 million. In the fall of 2005, the company cut this projection to $120 million.


Affy also cut its full-year 2005 product-related revenue projection, also for a second time. The company originally projected to generate $390 million in product-releated receipts in 2005, but in the fall of 2005, the firm cut that figure 6 percent to $365 million. Yesterday, Affy further cut that projection, this time to $350 million, or an additional 4.3 percent.


Also yesterday, Affy cut its total 2005 revenue projection by $40 million, or 9.9 percent, to $365 million.


"Affymetrix is experiencing growing pains as it both innovates and commercializes new products in high potential markets," said CEO Stephen Fodor. "We are carrying record orders into 2006 and expect to achieve around 15 percent top-line growth for the full year."

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.